Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Bhavesh Shah,1 Rickard Sandin,2 Yun Liu,3 Laura R Bobolts,4 Yannan Hu,3 Isha Mol,3 Alexander Schepart,5 David M Hughes,5 Jim Hart,5 Patrick Hlavacek5 1Boston Medical Center, Boston, MA, USA; 2Pfizer AB, Stockholm, Sweden; 3Cytel, Rotterdam, Netherlands; 4Oncohealth, Pompano Beach, FL, USA; 5Pfizer I...

Full description

Saved in:
Bibliographic Details
Main Authors: Shah B, Sandin R, Liu Y, Bobolts LR, Hu Y, Mol I, Schepart A, Hughes DM, Hart J, Hlavacek P
Format: Article
Language:English
Published: Dove Medical Press 2025-04-01
Series:ClinicoEconomics and Outcomes Research
Subjects:
budget impact model
cost-of care
medicare
multiple myeloma
triple-class exposed
triple-class refractory
us commercial payer
Online Access:https://www.dovepress.com/economic-impact-of-elranatamab-for-treatment-of-patients-with-relapsed-peer-reviewed-fulltext-article-CEOR
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.dovepress.com/economic-impact-of-elranatamab-for-treatment-of-patients-with-relapsed-peer-reviewed-fulltext-article-CEOR

Similar Items